Preclinical data show that the compound selectively inhibits CCR2-mediated migration of monocytes and does not inhibit migration mediated by additional chemokine receptors, even when the compound is given at high doses. This high degree of target specificity can be an important basic safety feature designed to enable CCX140 to be effective while avoiding negative effects. Related StoriesStudy explores diabetes screening for individuals with serious mental illnessSleep loss reduces insulin sensitivity, boosts diabetes riskBetalin launches fresh EMP technology that could transform diabetes treatment’The initiation of the Phase II trial for CCX140 is an important step forward in identifying a novel treatment for diabetes, a disease for which an unmet medical dependence on safe and easy therapies persists,’ stated Thomas J.About 60 % of depressed patients usually do not respond completely to the first medication. Consequently, doctors frequently must prescribe a different medicine over and over before finding one which works. ‘It could greatly benefit our individuals if we’re able to predict in advance whether confirmed medication will be effective for a particular patient,’ Halaris stated. The Loyola research involved 35 sufferers who required escitalopram for main depressive disorder. Escitalopram belongs to a course of antidepressants known as selective serotonin reuptake inhibitors .